Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

2007 a pivotal year for GW Pharmaceuticals

Despite the hurdles, GW has made considerable progress in developing the drug pipeline. Sativex was approved in Canada in 2005 as a treatment for symptomatic relief of neuropathic pain in adults.

Preliminary results from GW Pharmaceuticals (AIM: GWP) helped the share price recover some of the losses from a disappointing 2006 share performance. GW develops and manufactures cannabinoid medicines, including Sativex which is currently available in Canada on prescription and in restricted use in Spain. If you hadn?t already guessed, GW makes pain-relief drugs based on cannabis. And it is this use of cannabis as a medicinal form of pain relief that has slowed the commercialisation of the product. One can only imagine the additional scrutiny a new drug must undergo when the primary source of the medicine is a plant that falls foul of most western laws.

Despite the hurdles, GW has made considerable progress in developing the drug pipeline. Sativex was approved in Canada in 2005 as a treatment for symptomatic relief of neuropathic pain in adults. The market may be relatively small in Canada, but the approval gained the company much needed revenues and breathing space to continue working on approval processes for Sativex in other territories. Since the initial approval in Canada, the company has applied for additional approval to use the product in the treatment of pain in patients with advanced cancer that cannot be relieved by opioid medications.

The company?s strategy for Sativex is to seek approval for its use in four particular areas; MS spasticity, MS neuropathic pain, peripheral neuropathic pain and cancer pain. GW is targeting multiple applications across various territories including Europe, United States, Canada and the United Kingdom. Success in seeking approval for the product is patchy, but the company does have regulatory applications and Phase III trials ongoing in a number of target markets, so this is certainly not an early stage drug development company. It should be noted that GW is caring out Phase III trials for each of its four core areas of pain relief. Therefore regulatory approval for one type of pain relief does not guarantee approval for use in other types of pain relief. This also means that GW has to carry out multiple Phase III trials in different territories until it has built up enough data to submit directly to regulatory bodies without having to duplicate the work. The key to GW?s success in 2007 will be gaining regulatory approval beyond Canada and limited use in Spain. Clearly the big market the crack is the United States, but Europe and the United Kingdom are important markets too.

Perhaps unusually, Canada approved the drug before the United States. The two countries health agencies tend to work in parallel to one another and drug approvals tend to occur in the United States first with Canada shortly following. It may just be that GW?s acceptance in Canada and relative success to date may help boost its chances of approval in the United States. Preliminary results for the period ending 30th September, 2006 were in line with market expectations. The company had revenues of £1.98 million of which £1.25 million came directly from Sativex sales. The company also booked a one off £12 million European licence signature fee from Almirall which will be recognised over 15 years. Cash in the bank surged to £19.9 million and the net loss was £11.9 million.

GW isn?t valued on revenues however; instead it is valued on the potential revenue strength of Sativex and other drugs the company is researching. The most important milestone in 2007 will likely be the signing of a licensing partner for the United States and regulatory approval in four European countries to market Sativex for MS Spasticity.

Join our Crypto, Blockchain and Cannabis Telegram group here
View full GWP profile View Profile

GW Pharmaceuticals Timeline

Related Articles

June 20 2018
“FLU-v is designed to protect against a broad range of influenza viral strains and this includes unexpected seasonal strains or a potentially devastating pandemic strain"
April 01 2018
The company is in the process of raising £5mln, with a possible further £1mln through a share issue at 52.5p
tumour cells
July 25 2018
Sign-off by the US Food & Drug Administration is considered the "global standard for approval", the company said

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use